IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
+24.54%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$278M
AUM Growth
+$278M
(+28%)
Cap. Flow
+$20M
Cap. Flow
% of AUM
7.22%
Top 10 Holdings %
Top 10 Hldgs %
51.21%
Holding
67
New
9
Increased
19
Reduced
11
Closed
4
Top Buys
| 1 |
Acadia Pharmaceuticals
ACAD
|
$11.5M |
| 2 |
Merck
MRK
|
$7.55M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$6.22M |
| 4 |
Halozyme
HALO
|
$4.52M |
| 5 |
Biogen
BIIB
|
$4.15M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$17M |
| 2 |
Insmed
INSM
|
$7.7M |
| 3 |
PTC Therapeutics
PTCT
|
$5.85M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$4.13M |
| 5 |
Incyte
INCY
|
$2.84M |
Sector Composition
| 1 | Healthcare | 99.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vertex Pharmaceuticals
VRTX
$100B
| $20.4M | 7.36% | 93,422 +9,400 | +11% | +$2.06M |
|
2
Gilead Sciences
GILD
$140B
| $19.1M | 6.86% | 293,284 -23,000 | -7% | -$1.49M |
|
3
Amgen
AMGN
$155B
| $15.9M | 5.73% | 66,000 | – | – |
|
|
4
Acadia Pharmaceuticals
ACAD
$4.38B
| $14.4M | 5.18% | 336,000 +268,000 | +394% | +$11.5M |
|
5
Neurocrine Biosciences
NBIX
$13.8B
| $14.3M | 5.16% | 133,300 -14,000 | -10% | -$1.5M |
|
|
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $14.1M | 5.08% | 390,000 +172,000 | +79% | +$6.22M |
|
|
7
Biogen
BIIB
$19.4B
| $13.6M | 4.88% | 45,700 +14,000 | +44% | +$4.15M |
|
|
8
Regeneron Pharmaceuticals
REGN
$61.5B
| $10.8M | 3.9% | 28,830 -11,000 | -28% | -$4.13M |
|
|
STML
9
DELISTED
Stemline Therapeutics, Inc.
STML
| $10.3M | 3.69% | 965,245 +130,000 | +16% | +$1.38M |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $9.31M | 3.35% | 86,141 -16,000 | -16% | -$1.73M |
|
11
BioMarin Pharmaceuticals
BMRN
$11.2B
| $8.81M | 3.18% | 104,284 +17,000 | +19% | +$1.44M |
|
12
Illumina
ILMN
$15.8B
| $8.32M | 3% | 25,100 | – | – |
|
|
AMRN
13
Amarin Corp
AMRN
$311M
| $8.32M | 3% | 388,000 +129,000 | +50% | +$2.76M |
|
|
14
Merck
MRK
$210B
| $7.55M | 2.72% | +83,000 | New | +$7.55M |
|
|
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
| $7.31M | 2.63% | 64,000 -2,400 | -4% | -$274K |
|
|
16
Incyte
INCY
$16.5B
| $5.59M | 2.01% | 64,000 -32,500 | -34% | -$2.84M |
|
|
17
PTC Therapeutics
PTCT
$3.92B
| $5.47M | 1.97% | 114,000 -122,000 | -52% | -$5.85M |
|
|
18
Halozyme
HALO
$8.56B
| $5.45M | 1.96% | 307,633 +255,000 | +484% | +$4.52M |
|
19
Sarepta Therapeutics
SRPT
$1.78B
| $5.17M | 1.86% | 40,100 +14,000 | +54% | +$1.81M |
|
20
Alnylam Pharmaceuticals
ALNY
$58.5B
| $4.99M | 1.8% | 43,300 +9,500 | +28% | +$1.09M |
|
21
KalVista Pharmaceuticals
KALV
$678M
| $4.92M | 1.77% | 277,433 +100,000 | +56% | +$1.77M |
|
|
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.63M | 1.67% | 35,900 +25,000 | +229% | +$3.22M |
|
23
Ionis Pharmaceuticals
IONS
$6.79B
| $3.25M | 1.17% | 53,781 +7,600 | +16% | +$459K |
|
24
Nektar Therapeutics
NKTR
$568M
| $3.02M | 1.09% | 140,000 +80,000 | +133% | +$1.73M |
|
|
XLRN
25
DELISTED
Acceleron Pharma Inc.
XLRN
| $3.02M | 1.09% | 57,000 +27,000 | +90% | +$1.43M |
|